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Evidence That CXCL16 Is a Potent Mediator of Angiogenesis
and Is Involved in Endothelial Progenitor Cell Chemotaxis
Studies in Mice With K/BxN Serum–Induced Arthritis
Takeo Isozaki,1 Ali S. Arbab,2 Christian S. Haas,1 M. Asif Amin,1 Monica D. Arendt,1
Alisa E. Koch,3 and Jeffrey H. Ruth1
Objective. To examine the possibility that
CXCL16 recruits endothelial cells (ECs) to developing
neovasculature in rheumatoid arthritis (RA) synovium.
Methods. We utilized the RA synovial tissue
SCID mouse chimera system to examine human micro-
vascular EC (HMVEC) and human endothelial pro-
genitor cell (EPC) recruitment into engrafted human
synovium that was injected intragraft with CXCL16-
immunodepleted RA synovial fluid (SF). CXCR6-
deficient and wild-type (WT) C57BL/6 mice were primed
to develop K/BxN serum–induced arthritis and evalu-
ated for angiogenesis. HMVECs and EPCs from human
cord blood were also examined for CXCR6 expression,
by immunofluorescence and assessment of CXCL16
signaling activity.
Results. CXCR6 was prominently expressed on
human EPCs and HMVECs, and its expression on
HMVECs could be up-regulated by interleukin-1.
SCID mice injected with CXCL16-depleted RA SF ex-
hibited a significant reduction in EPC recruitment. In
experiments using the K/BxN serum–induced inflam-
matory arthritis model, CXCR6/ mice showed pro-
found reductions in hemoglobin levels, which correlated
with reductions in monocyte and T cell recruitment to
arthritic joint tissue compared to that observed in WT
mice. Additionally, HMVECs and EPCs responded to
CXCL16 stimulation, but exhibited unique signal trans-
duction pathways and homing properties.
Conclusion. These results indicate that CXCL16
and its receptor CXCR6 may be a central ligand/
receptor pair that is closely associated with EPC re-
cruitment and blood vessel formation in the RA joint.
Rheumatoid arthritis (RA) is a debilitating in-
flammatory joint disorder affecting 2% of the popula-
tion worldwide (1). Autoimmune-mediated inflamma-
tion has long been known to be the primary mechanistic
component of the cartilage and bone destruction ob-
served in RA joints (2). Growth of new blood vessels
(i.e., neovascularization) in the joint lining (synovium) is
characteristic of this inflammatory response and is ob-
served early in RA pathogenesis (3).
Synovial neovascularization plays a pivotal role
in the progression of RA, by creating a direct conduit
by which circulating leukocytes that exacerbate inflam-
mation can enter the joint. Neovascularization occurs
by one of two mechanisms: angiogenesis (the replica-
tion and reorganization of preexisting microvascular
endothelial cells [ECs]) (4) or vasculogenesis (the re-
cruitment of endothelial progenitor cells [EPCs] that
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subsequently incorporate into the existing tissue and
differentiate into mature functional ECs) (5).
Chemokines are small soluble molecules that
recruit destructive proinflammatory immune cells to RA
synovium. Some CXC chemokines exhibit angiogenic
activity (6–9). Although studies to characterize the
actions of chemokines have identified many in vitro
functions, there is still a need for information regarding
the specific role of chemokines in animal models of RA.
Interestingly, a recent study showed that a high percent-
age of primary bone marrow–derived murine mesenchy-
mal stem cells (mean  SEM 96  2%) expressed
CXCR6, the only known receptor for CXCL16, on their
cell surface; of note, CXCR6 was expressed on a high
proportion of human bone marrow–derived mesenchy-
mal stem cells as well (95  1%) (10). Considering the
known function of this receptor in relation to recruit-
ment and homing of immune cells (11), it is reasonable
to hypothesize that CXCR6 may also be involved in the
recruitment and homing of mesenchymal stem cells to
inflamed tissue, likely for the purpose of tissue regener-
ation and/or vasculogenesis (10).
There is growing evidence suggesting that EPCs
contribute to the homeostasis of the physiologic vascular
network (12) and, additionally, contribute to vascular
remodeling of RA synovium by recruiting bone marrow–
derived circulating EPCs (13). We have previously dem-
onstrated very highly elevated concentrations of soluble
CXCL16 compared to other chemokines in RA synovial
fluid (SF) (11). Our present data show that CXCL16
has a distinct role as an important factor in EC angio-
genesis and EPC recruitment to human synovium
in vivo. We found that both human microvascular
ECs (HMVECs) and EPCs express CXCR6 and that
HMVECs up-regulate CXCR6 in response to proin-
flammatory stimuli. Thus, we believe selective regulation
of EC-mediated migration may be a viable therapeutic
strategy for limiting vasculogenesis in RA synovium.
MATERIALS AND METHODS
Rodents. Animal care at the Unit for Laboratory
Animal Medicine at the University of Michigan is supervised
by a veterinarian and operated in accordance with federal
regulations. SCID mice were obtained from the National
Cancer Institute. Breeder pairs of CXCR6-knockout C57BL/6
mice (a kind gift from Dr. Daniel R. Littman, New York
University, New York, NY) and age- and weight-matched
wild-type (WT) C57BL/6 mice were bred in-house according to
the guidelines of the University Committee on the Use and
Care of Animals. All experiments were performed on female
mice and were initiated when the animals were 4–6 weeks old.
The mice were provided food and water ad libitum throughout
the entire study and were housed in sterile rodent micro-
isolator caging with filtered cage tops in a specific pathogen–
free environment. All efforts were made to reduce stress or
discomfort to the animals.
Isolation of CD34 EPCs from cord blood. Human
EPCs were isolated from cord blood from granulocyte colony-
stimulating factor–mobilized leukapheresis samples on the
basis of CD133 expression, using an antibody-coupled mag-
netic bead cell isolation system (Stem Cell Technologies).
Human umbilical cord blood was collected by the method of
Moore et al (14), as previously described (13). To confirm
purity of the EPCs, isolated cell populations were analyzed by
flow cytometry as previously described (15,16). EPCs with
appropriate cell markers (CD34, CD133, CD14) were
used in chimeras and related in vitro studies.
Fluorescence microscopy of ECs. HMVECs (passage 9
or lower) were plated, on 8-well Lab-Tek chamber slides at
20,000/well, in 0.1% bovine serum albumin endothelial basal
medium (EBM) without antibiotics. Some HMVECs were
stimulated with interleukin-1 (IL-1) for 24 hours. The next
day, cells were washed with phosphate buffered saline (PBS)
and fixed with 4% formalin for 30 minutes at room tempera-
ture, washed again with PBS, and fixed with cold acetone for
20 minutes. EPCs were also plated at 20,000/well in 8-well
Lab-Tek chamber slides in Stem-span and fixed similarly.
For staining, HMVECs and EPCs were blocked with 20%
fetal bovine serum (FBS) and 5% donkey serum for 1 hour
at 37°C. Mouse anti-human CXCR6 antibody (R&D Systems)
or mouse anti-human von Willebrand factor (vWF) antibody
(Dako) was used as primary antibody. Fluorescence-
conjugated secondary antibody was purchased from Molecular
Probes, and cell nuclei were stained with DAPI (Molecular
Probes).
Immunofluorescence analysis for leukocytes. Immuno-
fluorescence histologic analysis was performed as previously
described (11). Briefly, rat anti-mouse CD3 or CD14 anti-
bodies (final concentration 10 g/ml; both from BD Biosci-
ences) were added as primary antibodies and incubated for
1 hour at 37°C. Rat IgG was used as a negative control.
After washing twice with PBS, Alexa Fluor 488–labeled goat
anti-rat antibody was added and incubated for 1 hour at 37°C.
After washing with PBS, nuclei were counterstained with
DAPI and coverslipped. Serial sections were examined with a
BX51 Fluorescence Microscope System using DP Manager
imaging software (Olympus). Photographs were merged, and
CD3 or CD14 macrophages were identified by fluores-
cence microscopy.
HMVEC chemotaxis assay. HMVECs (BioWhittaker)
were maintained in growth factor complete EBM supple-
mented with 10% FBS. Cells (from passage 7–10) did not
display discernible phenotypic changes when observed before
each assay. Cells were maintained at 37°C in a 5% CO2 atmo-
sphere. HMVEC migration in vitro was tested using a modified
48-well Boyden chemotaxis chamber (Neuro Probe) as previ-
ously described (17), and the data were expressed as the
number of cells migrating per well.
In vitro capillary morphogenesis assay. HMVECs
were suspended in EBM with 0.1% FBS and seeded in
Lab-Tek chamber slides on growth factor–reduced Matrigel
(Becton Dickinson) at a density of 1.6 104 cells per chamber.
Immediately after plating, cells were treated with recombinant
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human CXCL16 (100 ng/ml), 4-phorbol 12-myristate 13-
acetate (PMA; 50 nmoles/liter) (as a positive control), or
DMSO (included as a negative control since PMA is dissolved
in DMSO). After 18 hours, capillary morphogenesis was
examined by phase-contrast microscopy and node formation
evaluated by an investigator who was blinded with regard to
the experimental setup. Capillary formation was defined as the
induction of a minimum of 3 separate capillary events by
HMVECs in growth factor–reduced Matrigel, as previously
described (17).
Western blotting and cell signaling in HMVECs and
EPCs. Western blotting of ECs was performed as previously
described (11,18). Briefly, HMVECs and EPCs were plated at
1  105 in 0.1% FBS/EBM (HMVECs) or Stem-span media
(EPCs) and stimulated with CXCL16 (80 ng/ml). Blots were
probed using rabbit antibodies to selected phosphorylated
signaling molecules (anti–phospho-p38, anti–phospho-ERK-
1/2, anti–phospho-JNK, and anti–phospho-Src; all from Cell
Signaling Technology). The immunoblots were stripped and
reprobed with rabbit antibody to the total form of each
signaling molecule (containing phosphorylated and nonphos-
phorylated forms of the same molecule) to verify equal load-
ing. In some experiments, HMVECs and EPCs were probed
for CXCR6 expression with and without IL-1 stimulation.
The immunoreactive protein bands were visualized by en-
hanced chemiluminescence (Amersham Biosciences). Densi-
tometric analysis of the bands was performed using Un-Scan-It
software, version 5.1 (Silk Scientific).
RA SF neutralization studies. For neutralization of
CXCL16, diluted SF (1:300 with PBS) was preincubated with a
neutralizing polyclonal goat anti-human CXCL16 antibody
(catalog no. AF976; R&D Systems) at a concentration of
135 ng/100 l diluted SF (from undiluted SF samples contain-
ing45 ng/ml CXCL16). Control (sham-depleted) SF samples
were incubated in a similar manner but with a corresponding
control nonspecific antibody (goat IgG), as recommended by
the manufacturer (R&D Systems) and as previously described
in experiments using RA SF (19).
K/BxN serum–induced arthritis model. To generate
arthritic K/BxN mice, K/B mice were crossed with NOD/ShiLtJ
mice as previously described (20). Naive mice (ages 5–7 weeks)
were injected intraperitoneally with 150 l of K/BxN mouse
serum; the day of the first injection was considered to be day 0
of arthritis. Another injection of 150 l of K/BxN mouse serum
was administered on day 2. Robust arthritis with severe
swelling of the joints typically developed on day 5. Articular
index scores were determined and joint circumference mea-
sured starting on day 0 and at least every other day up to day
23 after induction of arthritis, as described previously for
adjuvant-induced arthritis in the rat (21). Mouse ankles were
harvested for histologic assessment or made into tissue homog-
enates.
Clinical assessment of K/BxN serum–induced arthri-
tis. Clinical parameters in mice with arthritis were assessed
from day 0 to day 23. The articular index consisted of a 0–4
scale, where 0  no swelling or erythema, 1  slight swelling
and/or erythema, 2  low-to-moderate edema, 3  pro-
nounced edema with limited use of the joint, and 4 excessive
edema with joint rigidity. Ankle circumference was deter-
mined as previously described (21). Briefly, 2 perpendicular
diameters of the joint were measured with a caliper (Lange
caliper; Cambridge Scientific), and ankle circumference was
determined using the geometric formula 2 [(a2  b2/2)] ,
where a is the laterolateral diameter and b is the anteroposte-
rior diameter. In each ankle joint, the mean value of the 2
perpendicular diameters was calculated; these 4 values were
then used to calculate the mean ankle circumference for the
individual animal. Data are depicted as the increase in ankle
circumference compared to the baseline (day 0) value. All
measurements were performed by observers who were blinded
with regard to the experimental conditions.
Determination of hemoglobin (Hgb) concentrations in
ankle homogenates from mice with K/BxN–induced arthritis.
For measurement of Hgb concentration (a reflection of the
number of blood vessels in the tissue [17]), mouse joints were
homogenized as previously described (22). Hgb levels were
measured by adding 25 l of homogenate mixed with 25 l
of 3,3,5,5-tetramethylbenzidine reagent to 96-well plates.
Samples were incubated for 5 minutes at room temperature,
and absorbance was read with a Microplate Manager enzyme-
linked immunosorbent assay reader (BioTek Instruments) at
450 nm. Hgb concentrations were determined by comparison
with a standard curve. Values were normalized by dividing the
Hgb concentration by the amount of total protein in the
homogenate.
HMVEC and EPC migration to engrafted tissue in the
synovial tissue (ST) SCID mouse chimera. SCID mice were
grafted as previously described (11). We utilized normal and
RA ST SCID mouse chimeras to evaluate HMVEC and EPC
trafficking from the peripheral blood to engrafted ST. Once
grafts took, fluorescent (PKH26) dye–tagged HMVECs or
EPCs were injected intravenously into mice engrafted with
either normal or RA ST. ECs were allowed to circulate for
at least 48 hours (for HMVECs) to 72 hours (for EPCs). The
different incubation times for HMVECs and EPCs reflect the
speed of incorporation of HMVECs compared to EPCs, as we
found that mature HMVECs are recruited and integrated into
the vasculature of engrafted synovium faster than EPCs.
Messenger RNA (mRNA) extraction and quantitative
reverse transcription–polymerase chain reaction (PCR). SCID
mouse grafts were snap-frozen and prepared for mRNA
analysis. Total RNA was isolated from snap-frozen tissue
using RNeasy Mini RNA isolation kits in conjunction with
QIAshredders according to the protocol recommended by
the manufacturer (Qiagen). Following isolation, RNA was
quantified and checked for purity using a spectrophotometer
(NanoDrop Technologies). Complementary DNA (cDNA)
was then prepared using a Verso cDNA kit (Thermo Fisher
Scientific). Quantitative PCR was performed using Platinum
SYBR Green qPCR SuperMix-UDG according to the in-
structions of the manufacturer (Invitrogen). The primers used
for human CXCL16 and GAPDH were the same as used
previously (11). All samples were run in duplicate and analyzed
using Eppendorf software.
Statistical analysis. Results are expressed as the
mean  SEM. Statistical significance was analyzed by Stu-
dent’s t-test. P values less than 0.05 were considered significant.
RESULTS
CXCR6 expression on ECs. Western blot ana-
lysis demonstrated that HMVECs expressed CXCR6
and that CXCR6 could be up-regulated by IL-1
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(Figures 1A and B). Anti-human CXCR6 was used as
the primary antibody for detection of CXCR6 expres-
sion on HMVECs by immunofluorescence staining
(Figure 1C). HMVECs expressed CXCR6, with further
expression induced by IL-1 (Figures 1C and E). Con-
trol IgG staining is shown in Figures 1D, F, and H, and
control staining for EC-specific vWF is shown in Figure
1G. CXCR6 was also expressed on EPCs (see below).
Induction of HMVEC chemotaxis by CXCL16.
We tested the ability of CXCL16 to induce HMVEC
migration in vitro. HMVEC chemotactic activity peaked
with CXCL16 at a concentration of 1 M and fell off at
a higher concentration (Figure 1I).
Demonstration by in vitro capillary morphogen-
esis assay that CXCL16 is angiogenic in vitro. Capillary
tube formation was determined by evaluation of nodular
contacts between at least 3 endothelial cell tubes under
blinded conditions, and the number of circular tube
network formations was counted. Consistent with the
chemotaxis results, CXCL16 induced tube formation
(Figures 2A–C).
Evidence that HMVEC and EPC migration to
engrafted tissue in ST SCID mouse chimeras is due to
CXCL16. In both normal ST and RA ST mouse chime-
ras, there appeared to be a reduced number of scattered
HMVECs migrating toward CXCL16 (Figures 2D and
E). This can be explained by the finding of clumps of
HMVECs apparently forming vasculature, thus having
fewer scattered cells (Figure 2D). We also found that
tumor necrosis factor  (TNF), as well as CXCL16,
up-regulated CXCL16 expression in vivo. SCID mouse
grafts were snap-frozen and prepared for mRNA analy-
Figure 1. Human microvascular endothelial cells (HMVECs) express CXCR6 and are chemotactic for CXCL16. A and B, Western blots
demonstrating expression of CXCR6 by HMVECs and up-regulation of this expression by interleukin-1 (IL-1) (B), with the results normalized
to -actin and quantified (A). C, HMVEC expression of CXCR6 (red fluorescence staining). D, Control IgG staining of HMVECs. E, Intense
CXCR6 staining in HMVECs (arrow) in response to stimulation with recombinant human IL-1. F, Control IgG staining of HMVECs with IL-1
stimulation, showing a lack of staining for CXCR6 (arrow). G, Positive staining for von Willebrand factor (vWF) in HMVECs (arrow) in response
to stimulation with IL-1. H, Control IgG staining of HMVECs with IL-1 stimulation, showing induction of vWF. I, Dose-dependent migration
of HMVECs toward CXCL16. HMVECs were chemotactic for CXCL16 at 1 M, indicating that CXCL16 functions as an endothelial cell
chemotactic factor. Values in A and I are the mean  SEM; n represents the number of experiments. NS  no stimulus; bFGF  basic fibroblast
growth factor; PBS  phosphate buffered saline. In C–H, original magnification  40. Color figure can be viewed in the online issue, which is
available at http://onlinelibrary.wiley.com/doi/10.1002/art.37981/abstract.
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sis and, as seen in Figure 2F, both TNF and CXCL16
up-regulated CXCL16 mRNA expression in the RA ST
SCID mouse chimera system. Figure 2G shows
HMVECs migrating into RA ST in the RA ST SCID
mouse chimera, including images of red fluorescent
HMVECs and of ST stained for both anti-mouse and
Figure 2. CXCL16 forms tubes in Matrigel and in human synovial tissue (ST) SCID mouse chimera. A–C, Examples of capillary tube formation,
determined by evaluating circular tube networks (A) (arrowheads) and nodular contacts between endothelial cell tubes (B and C) (arrows). Tube
formation was induced by treatment with CXCL16, compared to PBS. DMSO and 4-phorbol 12-myristate 13-acetate (PMA) were studied as negative
and positive controls, respectively. Bars in A and B show quantification of the results, expressed as the mean  SEM; n represents the number of
experiments. D, Normal ST section, showing scattered dye-tagged HMVECs migrating in response to PBS (arrow in left panel) and clearly organized
migration of dye-tagged HMVECs in response to intragraft administration of CXCL16 (arrow in right panel). E, Mean SEM numbers of scattered
HMVECs observed in response to CXCL16 versus PBS in rheumatoid arthritis (RA) ST SCID mouse chimera; n represents the number of sections
studied. Fewer scattered HMVECs were observed in response to CXCL16, likely due to HMVEC clumping. F, Mean SEM expression of CXCL16
mRNA in response to intragraft injection of CXCL16 or tumor necrosis factor  (TNF), showing up-regulation of CXCL16 by both CXCL16 and
TNF; n represents the number of experiments. G, Serial section of PKH26 dye–tagged HMVECs migrating into engrafted human ST (left), serial
section obtained from the same tissue sample and stained with fluorescein isothiocyanate–labeled rabbit anti-mouse/human (M/H) vWF (middle),
and merged image of left and middle panels (right). Green color identifies mouse endothelium (arrow M) and yellow color identifies human
endothelium (arrow H), demonstrating the formation of a true chimera. Experiments were performed in triplicate. In A–D and G, original
magnification  40. See Figure 1 for other definitions.
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anti-human vWF (stains all ECs), and a merged image
revealing mouse and human endothelium integrated
into the developing vasculature, indicating the formation
of a true vascular chimera.
Human CD34 EPCs can be isolated and char-
acterized from cord blood. Anti-human CXCR6 was
used as the primary antibody for detection of CXCR6
expression on human EPCs by immunofluorescence
staining (Figure 3A). Central to all of these studies was
our ability to generate pure populations of human EPCs.
Cells were sorted and purified (Figure 3B), and we
confirmed that pure populations of cells could be suc-
cessfully isolated by receptor expression. We also
showed, by Western blotting, that CXCR6 was highly
expressed on EPCs but, unlike HMVECs, was not
up-regulated by IL-1 (Figures 3C and D). EPCs also
migrated toward the chemotactic stimulus (i.e.,
CXCL16), as evidenced by the observation that more
fluorescent dye–tagged cells were found in the normal
ST graft (Figure 3E), not appearing to form clumps
Figure 3. Endothelial progenitor cells (EPCs) express CXCR6 and migrate to CXCL16 in vivo. A, EPC expression of CXCR6 (yellow/orange
fluorescence staining) (arrow). Control IgG staining is also shown. Original magnification 40 in upper panels; 400 in lower panels. B, Cell sorting
and purification results. EPCs expressed CD31 and could also be identified and sorted by CD34 expression. More than 95% of these cells were
AC133. The isolated cell population also expressed CXCR4 (the receptor for stromal cell–derived factor 1/CXCL12), even without any external
stimuli (e.g., cytokines, lipopolysaccharide, 4-phorbol 12-myristate 13-acetate). C and D, Western blots demonstrating expression of CXCR6 by EPCs
and no effect of IL-1 on this expression (D), with the results normalized to -actin and quantified (C). Values are the mean  SEM; n represents
the number of experiments. E and F, Infiltration of EPCs into engrafted tissue in SCID mice engrafted with normal human synovium. EPC
infiltration to engrafted tissue was increased 3-fold in mice receiving intragraft injections of CXCL16 compared to mice receiving intragraft
injections of PBS (E), and robust recruitment of fluorescent dye–tagged EPCs was observed in mice injected with sham-immunoneutralized
rheumatoid arthritis (RA) synovial fluid (SF) compared to mice injected with CXCL16 antibody (Ab)–treated RA SF (F). Values are the mean 
SEM; n represents the number of sections counted. G, Images of fluorescence staining from the experiments described in F, demonstrating stronger
recruitment of EPCs (arrows) in engrafted tissue injected with sham-immunoneutralized RA SF (left) than in engrafted tissue injected with CXCL16
antibody–treated RA SF (right). Original magnification 10. See Figure 1 for other definitions. Color figure can be viewed in the online issue, which
is available at http://onlinelibrary.wiley.com/doi/10.1002/art.37981/abstract.
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characteristic of HMVECs. Human cord blood prepara-
tions typically yield 1.5–2  106 CD133 EPCs per
preparation, with purities of 	95%.
EPC migration to engrafted tissue injected with
CXCL16-depleted RA SF. Injection of RA SF allows for
neutralization studies, as a single chemokine can be
neutralized from the RA SF before injection, for exam-
ination of its singular role in cellular recruitment and
integration into the implanted tissue. Mice engrafted
with normal ST that received intragraft injections of
CXCL16-depleted RA SF (CXCL16- and sham-
neutralized RA SF diluted 1:300 in PBS injected at
100 l/graft) exhibited a robust reduction in EPC mi-
gration compared to the sham-depleted control group
(n  9 tissue sections from 3 different mice per group)
(Figures 3F and G). This indicates that CXCL16 con-
tained within the RA SF is directly responsible, in part,
for EPC migration into normal human synovium.
Reduced joint swelling, histologic abnormality,
and vascularity following K/BxN serum transfer in
CXCR6/ mice compared to WT mice. On day 9 after
the initial injection of K/BxN serum, severe redness
and swelling of the joints was observed in WT mice, but
not in CXCR6/ mice (Figure 4A). In addition, the
articular index score and degree of joint swelling were
significantly reduced in CXCR6/ mice compared to
WT mice beginning on day 5 (Figure 4B). Joint tissue
sectioned from WT and CXCR6/ mice with K/BxN
serum–induced arthritis was stained with hematoxylin
and eosin for histopathologic assessment. As shown in
Figure 4C, cellular infiltration on day 9 was enhanced in
WT mice compared to CXCR6/ mice.
We also evaluated the number of vessels from
the same tissue, based on vWF expression identified
using immunofluorescence analysis. In these experiments,
CXCR6-deficient mice with K/BxN serum–induced ar-
thritis were shown to have a profound reduction in blood
vessel numbers (Figures 4C and D). To validate these
findings, we assessed concentrations of Hgb, a measure
of total joint vascularity, in joint homogenates from the
same animals, according to previously described meth-
ods (17,22). CXCR6/ mice had significantly less Hgb
(normalized to total protein) compared to arthritic WT
mice (Figure 4D), confirming the histologic finding of
reduced vascularity in the arthritic joints of CXCR6/
mice.
Different CXCR6 regulation and CXCL16 sig-
naling pathways in HMVECs and EPCs. Western
blot experiments demonstrated that in HMVECs,
CXCL16 up-regulated phospho-p38, phospho–ERK-
1/2, and phospho-JNK, in a time-dependent manner
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Figure 4. CXCR6 deficiency reduces joint inflammation and vascu-
larity in K/BxN serum–induced arthritis. A, Representative clinical
images of inflamed joints from mice with K/BxN serum–induced
arthritis, showing significant edema and inflammation in the wild-type
(WT) mouse but not the CXCR6/ mouse. B, Articular index scores
and increases in joint circumference (Inc in joint circ) in WT and
CXCR6/mice (4 mice per group) following induction of arthritis via
K/BxN serum transfer. Compared to WT mice, CXCR6/ mice had
significantly lower articular index scores on days 5 and 7 and signifi-
cantly less joint swelling on day 5. Values are the mean  SEM; n
represents the number of joints assessed. C, Representative photomi-
crographs of 5-m–thick sections obtained on day 9, showing increased
cellular infiltration and severe tissue damage in the sample from a WT
mouse compared to that from a CXCR6/ mouse (left panels)
(hematoxylin and eosin stained) and reduced vascularity (based on
immunofluorescence staining for von Willebrand factor [vWF]) in the
sample from the CXCR6/mouse (right panels); control IgG staining
is also shown. Original magnification 40. D, Number of blood vessels
per high-power field (hpf) and concentration of hemoglobin (Hb) in
joint homogenates from WT and CXCR6/ mice on day 9. Both the
number of vessels and the concentration of hemoglobin were signifi-
cantly lower in the CXCR6/mice compared to the WT mice. Values
are the mean  SEM; n represents the number of sections counted.
Color figure can be viewed in the online issue, which is available at
http://onlinelibrary.wiley.com/doi/10.1002/art.37981/abstract.
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(Figures 5A–C), whereas phospho-Src was down-
regulated by CXCL16 (Figure 5D). In contrast, EPCs
were shown to signal through phospho-Src in response
to CXCL16, with up-regulation of phospho-p38 demon-
strated as well (Figures 5E and F). Thus, only phospho-
p38 was similarly regulated in HMVECs and EPCs, with
the other pathways differing between the two cell types
(Figure 5G).
Reduced leukocyte recruitment following K/BxN
serum transfer in CXCR6/ mice compared to WT
mice. In the joints of WT mice with K/BxN serum–
induced arthritis, prominent CD3 and CD14 expression
was observed (Figure 6A). In contrast, in CXCR6-
deficient mice with K/BxN serum–induced arthritis, the
numbers of both CD3 cells and CD14 cells were
profoundly reduced (Figures 6B and C).
DISCUSSION
RA is a debilitating inflammatory joint disease in
which microvascular expansion in the joint lining (syno-
vium) is a characteristic finding. Synovial neovascular-
ization occurs presymptomatically and is critical for
disease progression (23). Studies in rodents have shown
that inhibition of angiogenesis results in suppression of
arthritis as well (24); however, there are limited data to
quantify the effectiveness of therapies targeting potent
angiogenic chemokines or chemokine receptors. Nota-
bly, Jodon de Villeroche and colleagues (25) have shown
that increased numbers of circulating EPCs in patients
with RA correlate with the 28-joint Disease Activity
Score (26), signifying that EPCs are likely elevated and
recruited to inflamed tissue for the purposes of synovial
Figure 5. Signaling studies demonstrating activation of human microvascular endothelial cells (HMVECs) and endothelial progenitor cells (EPCs)
by CXCL16. A–F, Representative blots from experiments assessing activation or down-regulation of p38 (A), ERK-1/2 (B), JNK (C), and Src (D)
in HMVECs and of p38 (E) and Src (F) in EPCs. Upper and lower bands show the amount of each signaling molecule in phosphorylated form (p)
and in total (phosphorylated and nonphosphorylated) (T), respectively; therefore, for each signaling molecule the upper blot is an indication of the
amount of phosphorylated protein contained in the lower band. Results were quantified, and bars show the mean  SEM. P values are versus no
stimulus (NS). In HMVECs, phospho-p38, phospho-ERK-1/2, and phospho-JNK were activated in response to CXCL16, whereas phospho-Src was
down-regulated. In EPCs, phospho-p38 and phospho-Src were activated in response to CXCL16. G, Summary of the signaling results in HMVECs
and EPCs in response to CXCL16. Of note is the finding that both cell types signaled through phospho-p38, indicating that the angiogenic and/or
vasculogenic activity of CXCL16 could be targeted by phospho-p38 inhibition.
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vasculogenesis. Previous studies have demonstrated re-
duced severity of arthritis in mice that lack CXCL16
(27), suggesting that CXCR6 and its ligand CXCL16
may be important mediators of arthritis development.
Based on the expression of CXCR6 on HMVECs and
EPCs and the highly elevated expression of CXCL16
in RA SF (11), we believe CXCL16 is central to this
process.
Using a combined in vitro and in vivo approach,
we examined possible environmental cues that might
direct the migration, differentiation, and functional in-
corporation of HMVECs and EPCs into the microcircu-
latory system. Initially, we immunostained HMVECs
and EPCs to validate their expression of CXCR6, and
confirmed that CXCR6 expression by HMVECs could
be up-regulated in response to a proinflammatory stim-
ulus. Next, we examined the ability of CXCL16 to recruit
HMVECs and form tubes in vitro. Using a modified
Boyden chemotaxis system, we found that HMVECs
migrate to CXCL16 in a dose-dependent manner. We
then showed that HMVECs respond to CXCL16 in
Matrigel by forming tubes, in accordance with our
chemotaxis findings.
To examine the behavior of HMVECs in re-
sponse to CXCL16 in vivo, we injected CXCL16 intra-
graft into normal ST SCID mouse chimeras and found
that well-integrated HMVECs could be observed in the
engrafted synovium 48 hours postinjection, not as scat-
tered cells but as clumps of cells that appear to be
forming vessels and chimeric nodes with the surrounding
murine vasculature. EPCs also migrated in the SCID
mouse chimera system, and we showed that by depleting
RA SF of CXCL16, we could suppress EPC recruitment
by approximately two-thirds, confirming that CXCL16
contained within RA SF induces EPC migration from
the peripheral blood directly into engrafted human ST.
We also defined the CXCL16 signaling pathways for
both types of ECs and observed interesting divergences
between HMVECs (the mature phenotype) and EPCs.
We found that phospho-p38 expression was up-
regulated in both HMVECs and EPCs in response to
CXCL16, whereas phospho-Src expression was up-
regulated in EPCs but down-regulated in HMVECs. In
addition, HMVECs signaled in response to CXCL16 via
phospho-ERK-1/2 and phospho-JNK, whereas EPCs
did not. We surmise that ECs may signal differently in
response to CXCL16 based primarily upon the maturity
of the cell.
Although we demonstrated that HMVECs and
EPCs readily migrated in the SCID mouse chimera,
HMVECs integrated into the established vasculature at
Figure 6. CXCR6 deficiency results in reduced leukocyte recruitment to
inflamed joint tissue. Joints from wild-type (WT) and CXCR6/ mice
were harvested on day 9 of K/BxN serum–induced arthritis and CD3 and
CD14 expression was assessed by immunofluorescence staining. A, Prom-
inent expression of CD3 and CD14 (arrows) in the cells of WT mice,
which was profoundly reduced in CXCR6/ mice. Control IgG staining
is also shown. Original magnification 40. B and C,Quantification of the
number of CD3 cells (B) and CD14 cells (C) per high-power field
(hpf), showing significant reductions of both CD3 and CD14 in the joints
of CXCR6/mice. Values are the mean SEM; n represents the fields
counted per section. Color figure can be viewed in the online issue, which
is available at http://onlinelibrary.wiley.com/doi/10.1002/art.37981/
abstract.
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a much faster pace compared to EPCs, reminiscent of an
angiogenic response. Conversely, EPCs appeared to
home much like mononuclear cells (11) and did not
incorporate into existing vasculature as quickly, re-
sembling a more vasculogenic response. These findings
suggest that CXCL16 is a robust agonist of both angio-
genesis (HMVEC migration and incorporation) and
vasculogenesis (EPC migration), promoting both de novo
blood vessel formation in RA synovium and expansion
of the existing capillary network, by two independent
mechanisms. We showed that both CXCL16 and TNF
up-regulated CXCL16 mRNA expression in the SCID
mouse chimera, defining an amplification step for the
expression of CXCL16 in vivo. Based on these findings,
it is tempting to speculate that by inhibiting EC CXCL16
signaling via phospho-p38, both the angiogenic and the
vasculogenic processes stimulated by CXCL16 could be
disrupted, perhaps identifying a legitimate target for
inhibition of CXCL16-induced EC activity within the
RA joint.
We further validated our findings in experiments
in which K/BxN serum was injected into CXCR6/
mice. These studies showed that arthritis development is
attenuated in mice lacking CXCR6 compared to WT
mice. Indeed, while WT mice clearly displayed a robust
inflammatory phenotype, including functional deficits,
following arthritis induction, their CXCR6/ counter-
parts were comparatively only mildly affected, suggest-
ing that CXCR6 is a critical mediator of arthritis devel-
opment. This was supported by histologic findings
showing reduced inflammation in the joint tissue of
CXCR6/ mice after K/BxN serum transfer. We also
demonstrated reduced Hgb content in joint homoge-
nates from K/BxN serum–treated CXCR6/ mice, as
well as profound reductions in the number of cells
expressing vWF (EC marker), CD3 (T cell marker), and
CD14 (macrophage marker) in the joint tissue of these
mice compared to similarly-treated age- and weight-
matched WT mice.
It should be noted that CXCL16 can recruit other
cells, apart from ECs, that may produce angiogenic
factors, such as vascular endothelial cell growth factor
(VEGF). Indeed, our data demonstrate that CXCR6
deficiency results in profound reductions in monocytes
known to produce VEGF. However, our results, includ-
ing HMVEC chemotaxis and tube formation in Matrigel
(both performed in the absence of other cell types),
provide strong evidence that CXCL16 has a direct role
in the stimulation of angiogenic activity. Although
HMVECs are also capable of producing VEGF, which
may potentially confound our findings, it is important to
point out that our control experiments using only PBS
did not show substantial angiogenic activity in either the
HMVEC migration or tube formation assays. We then
confirmed these findings in vivo using both HMVECs
and EPCs (both shown to express CXCR6, the only
known CXCL16 receptor). These results, when consid-
ered in total, lead us to the conclusion that CXCL16
functions as both an angiogenic mediator and a potent
leukocyte recruitment factor.
Based on our findings demonstrating that
CXCL16 is involved in blood vessel formation in ar-
thritic joints, it is possible that the CXCL16/CXCR6
pathway may be a primary pathway in the recruitment of
EPCs from the bone marrow. This is supported by a
previous report that very high percentages of mesenchy-
mal stem cells from both humans and mice (	90%)
express CXCR6 (10). Consistent with this, we have
shown that EPCs and HMVECs prominently express
CXCR6, which might explain the significant reductions
in vascularity in CXCR6/ mice during arthritis devel-
opment. Interestingly, we also discovered that HMVECs
and EPCs regulate the expression of CXCR6 differently
when stimulated with IL-1, with rapid up-regulation of
HMVECs, but not EPCs, in response to IL-1. Notably,
we found that EPCs robustly express CXCR6 without a
need for further stimulation. It is tempting to speculate
that EPCs may require this receptor to navigate from the
bone marrow to inflamed tissue such as the RA joint.
It has been argued that EPCs may not be a viable
target for RA therapy, as these cells have not been
observed in appreciable numbers in inflamed synovium.
However, this same observation also raised concerns as
to whether EPC populations are truly being monitored
in vivo, and has imposed tremendous limitations on the
assessment of the biologic function of EPCs as well as
their potential use as a therapeutic target (28). In
support of the notion that EPCs have a proinflammatory
role, it was previously demonstrated that human EPCs
readily migrate to RA ST, compared to normal ST, in
the SCID mouse chimera (13), and these findings are in
complete accordance with the present results obtained
using a similar chimera model system. The most signif-
icant finding in the present study is that EPCs migrate
toward RA SF in vivo and that this effect can be
abrogated with the removal of CXCL16. We also have
shown that EC signaling pathways in response to
CXCL16 are different depending upon the maturity of
ECs and have demonstrated where the different path-
ways intersect, possibly identifying suitable targets for
intervention strategies. Overall, the present results pro-
vide further evidence that CXCL16 is a central proin-
flammatory chemokine in joints affected by RA, pro-
moting both vasculogenesis and angiogenesis and
ENDOTHELIAL PROGENITOR CELL RECRUITMENT TO RA SYNOVIUM VIA CXCL16 1745
contributing to the expansion of the neovasculature in
rheumatoid synovium.
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